Status:
UNKNOWN
Renji Alzheimer's Disease Neuroimaging Cohort Study
Lead Sponsor:
RenJi Hospital
Conditions:
Alzheimer Disease
Eligibility:
All Genders
40-80 years
Brief Summary
This study focuses on the population of Alzheimer disease (AD). Based on Aβ(A)-Tau(T)-Vascular(V)-Neurodegeneration(N) (ATV(N))-AD evaluation system of NIA-AA Association, it can accurately diagnose a...
Detailed Description
Alzheimer disease (AD) is the most common cognitive impairment disease, which is mainly manifested in memory loss, language function and logical thinking disorder, and ultimately leads to the loss of ...
Eligibility Criteria
Inclusion
- 1\) Age: 50-75 years old; 2) complaints of memory decline; 3) Education≥ 6 years; 4) Be able to cooperate with the whole neuropsychological examinations; 5) No PET-MRI or brain MRI contraindications; 6) Sign informed consent.
- normal control: 1) Age: 50-75 years old; 2) No complaints of memory decline; 3) Mini-Mental State Examination (MMSE) ≥ 26 points; 4) Education years ≥ 6 years; 5) Be able to cooperate with a full set of neuropsychological examinations; 6) No PET-MRI or brain MRI contraindications; 7) Sign informed consent.
Exclusion
- 1\) Serious mental illness; 2) Severe depression: Hamilton Depression Scale (HAMD-17) scores ≥ 24; 3) Serious heart, liver, kidney and other important organ diseases; 4) PET-MRI or brain MRI contraindications
Key Trial Info
Start Date :
February 14 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2023
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05433363
Start Date
February 14 2022
End Date
February 1 2023
Last Update
June 27 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Renji Hospital,Shanghai Jiao Tong University School of Medicine
Shanghai, China, 200127